|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014467,
umls-concept:C0019588,
umls-concept:C0024880,
umls-concept:C0027950,
umls-concept:C0030685,
umls-concept:C0086418,
umls-concept:C0132098,
umls-concept:C0391871,
umls-concept:C0680255,
umls-concept:C0886658,
umls-concept:C1280500,
umls-concept:C1283071,
umls-concept:C1879547,
umls-concept:C1963578
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1988-8-11
|
|
pubmed:abstractText |
The ability of nedocromil sodium, a new anti-inflammatory agent for the treatment of asthma, to inhibit activation of human eosinophils and neutrophils in vitro, has been studied using an adherence reaction (the "rosette" technique) as well as a cytotoxicity assay. We have also investigated the capacity of nedocromil sodium to inhibit IgE-dependent histamine release from human lung mast cells. The drug was a potent inhibitor (IC50 approx 5 x 10(-9)M) of fMLP-induced enhancement of eosinophil and neutrophil complement (C3b) and IgG (Fc) rosettes. There was also a comparable inhibition of enhancement, by fMLP, of eosinophil and neutrophil cytotoxicity (for complement-coated schistosomula of Schistosoma mansoni). Although nedocromil sodium also inhibited histamine release from human lung mast cells in a dose-dependent fashion its activity was relatively weak (IC30 5 x 10(-6)M) compared to its effect on granulocytes. These experiments support the view that the principal mode of action of nedocromil sodium is its capacity to inhibit the activation of inflammatory cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0105-4538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
268-76
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:2455454-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:2455454-Complement C3b,
pubmed-meshheading:2455454-Dose-Response Relationship, Drug,
pubmed-meshheading:2455454-Eosinophils,
pubmed-meshheading:2455454-Histamine Release,
pubmed-meshheading:2455454-Humans,
pubmed-meshheading:2455454-Mast Cells,
pubmed-meshheading:2455454-N-Formylmethionine Leucyl-Phenylalanine,
pubmed-meshheading:2455454-Nedocromil,
pubmed-meshheading:2455454-Neutrophils,
pubmed-meshheading:2455454-Quinolines,
pubmed-meshheading:2455454-Rosette Formation,
pubmed-meshheading:2455454-Time Factors
|
|
pubmed:year |
1988
|
|
pubmed:articleTitle |
Effects of nedocromil sodium (Tilade) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells.
|
|
pubmed:affiliation |
Department of Allergy & Clinical Immunology Cardiothoracic Institute, Brompton Hospital London, England.
|
|
pubmed:publicationType |
Journal Article
|
